MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3294
+0.0094
+2.94%
Closed 16:00 09/20 EDT
OPEN
0.3112
PREV CLOSE
0.3200
HIGH
0.3384
LOW
0.3000
VOLUME
52.65K
TURNOVER
--
52 WEEK HIGH
2.190
52 WEEK LOW
0.2700
MARKET CAP
8.43M
P/E (TTM)
-0.5230
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PHIO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PHIO News

  • Phio Pharmaceuticals (PHIO) Presents At H.C. Wainwright 21st Annual Global Investment Conference - Slideshow
  • Seeking Alpha - Article.4d ago
  • Phio Pharma collaborates with Carisma Therapeutics to evaluate self-delivering RNAi technology; shares up 19% premarket
  • seekingalpha.09/09 16:34
  • 27 Healthcare Stocks Moving In Monday's Pre-Market Session
  • Benzinga.09/09 12:42
  • Phio Pharmaceuticals Announces Research Collaboration with Carisma Therapeutics to Evaluate its Self-Delivering RNAi Technology to Enhance Macrophage-Based Adoptive Cell Therapy
  • PR Newswire.09/09 12:10

More

Industry

Biotechnology & Medical Research
+0.75%
Pharmaceuticals & Medical Research
+1.02%

Hot Stocks

Name
Price
%Change

About PHIO

Phio Pharmaceuticals Corp, formerly RXi Pharmaceuticals Corporation, is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) (sd-rxRNA) therapeutic platform. The Company’s focuses on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intratumoral injection. The Company’s pipeline include RXI-762 and RXI-804. Its sd-rxRNA compounds are designed to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. The Company is developing RXI-762 for the treatment of Melanoma, Ovarian cancer and other indications. RXI-804 is an sd-rxRNA compound that is designed to suppress the expression of immune checkpoint protein, TIGIT.
More

Webull offers Phio Pharmaceuticals Corp (PHIO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.